These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 24053777)
1. The transcriptional programme of the androgen receptor (AR) in prostate cancer. Lamb AD; Massie CE; Neal DE BJU Int; 2014 Mar; 113(3):358-66. PubMed ID: 24053777 [TBL] [Abstract][Full Text] [Related]
2. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
3. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells. Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564 [TBL] [Abstract][Full Text] [Related]
4. [New generation of androgen receptor antagonist in castration resistant prostate cancer]. Uemura H Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352 [TBL] [Abstract][Full Text] [Related]
5. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. Mitsiades N Cancer Res; 2013 Aug; 73(15):4599-605. PubMed ID: 23887973 [TBL] [Abstract][Full Text] [Related]
6. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1. Zaia A; Fraizer GC; Piantanelli L; Saunders GF Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth. Mashima T; Okabe S; Seimiya H Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811 [TBL] [Abstract][Full Text] [Related]
8. Androgen receptor antagonists for prostate cancer therapy. Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562 [TBL] [Abstract][Full Text] [Related]
9. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). Tsao CK; Galsky MD; Small AC; Yee T; Oh WK BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411 [TBL] [Abstract][Full Text] [Related]
10. Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer. Sato M; Johnson M; Zhang L; Gambhir SS; Carey M; Wu L Clin Cancer Res; 2005 May; 11(10):3743-9. PubMed ID: 15897571 [TBL] [Abstract][Full Text] [Related]
20. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. Shiota M; Yokomizo A; Naito S J Mol Endocrinol; 2011 Aug; 47(1):R25-41. PubMed ID: 21504942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]